Skip to main content

Advertisement

SpringerLink
Log in

Body shape, lipid, and cardiovascular complications of HIV therapy

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Metabolic complications of HIV therapy have emerged as a vexing problem for individuals living with HIV infection and their clinicians. These adverse effects threaten health and quality of life as well as adherence to HIV treatment. Among the most common metabolic complications confronting clinicians are body shape changes and dyslipidemia. The pathogenesis of these disorders remains elusive, challenging the development of treatment strategies particularly for fat redistribution. Switching from metabolically offensive antiretrovirals has yielded improvements in both body shape and dyslipidemia. In addition, therapeutic approaches that have been developed for the treatment of dyslipidemia in HIV-uninfected patients, can with important caveats be applied to HIV therapy-associated lipid disorders. Aggressive assessment of cardiovascular disease risk and intervention is likely to reduce the incidence of cardiovascular disorders in HIV-infected patients. Development of antiretrovirals with fewer metabolic adverse effects will reduce the incidence of these and similar disorders during HIV therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.

    Article  PubMed  CAS  Google Scholar 

  2. Miller KD, Jones E, Yanovski JA, et al.: Visceral abdominal fat accumulation associated with use of indinavir. Lancet 1998, 351:871–875.

    Article  PubMed  CAS  Google Scholar 

  3. van der Valk M, Gisolf EH, Reiss P, et al.: Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001, 15:847–855.

    Article  PubMed  Google Scholar 

  4. Mulligan K, Parker R, Komarow L, et al.: Mixed patterns of changes in central and peripheral fat following initiation of ART [abstract]. Proceedings from the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25, 2005.

  5. Bernasconi E: Metabolic effects of protease inhibitor therapy. AIDS Read 1999, 9:254–269.

    PubMed  CAS  Google Scholar 

  6. Schambelan M, Benson C, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society—USA panel. JAIDS 2002, 31:257–275.

    PubMed  Google Scholar 

  7. Lichtenstein KA, Ward DJ, Morman AC, et al.: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389–1398.

    Article  PubMed  CAS  Google Scholar 

  8. Gripshover B, Tien T, Saag M, et al.: Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men [abstract]. Proceedings from the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 10–14, 2003.

  9. Dong KL, Bausserman LL, Flynn MM, et al.: Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Def Syndr 1999, 21:107–113.

    CAS  Google Scholar 

  10. Mulligans K, Anastos K, Justman J, et al.: Fat distribution in HIV-infected women in the United States: dual energy X-ray absorptiometry (DEXA) substudy in the women’s interagency HIV Study. J Acquir Immune Defic Syndr 2004, 38:18–22.

    Google Scholar 

  11. Joly V, Flandre P, Meiffredy V, et al.: Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: results of a substudy from a comparative trial. AIDS 2002, 16:2447–2457.

    Article  PubMed  CAS  Google Scholar 

  12. Mulligan K, Tai VW, Algren H, et al.: Altered fat distribution in HIV-positive men on nucleoside analogue reverse transcriptase inhibitor therapy. J Acquir Immune Def Syndr 2001, 26:443–448.

    CAS  Google Scholar 

  13. Gallant JE, Staszewski S, Pozniak A, et al.: Long-term efficacy and safety of tenofovir DF (TDF): a 144 week comparison versus stavudine (d4T) in antiretroviral-naive patients. Proceedings from the 15th International Conference on AIDS. Bangkok, Thailand, July 11–16, 2004.

  14. Carr A, Workman C, Smith DE, et al.: Abacavir substitution for thymidine nucleoside analogues in HIV-infected patients with lipoatrophy: a randomized controlled open-label multicenter 24-week study. JAMA 2002, 288:207–215.

    Article  PubMed  CAS  Google Scholar 

  15. McComsey GA, Ward DJ, Hessenthaler SM, et al.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in HIV-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004 Jan 15;38(2):263–70.

    Article  PubMed  CAS  Google Scholar 

  16. Moyle G, Sabin C, Cartledge J, et al.: A 48 week, randomized, open-label comparative study of tenofovir DF versus abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART [abstract]. Proceedings from the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25, 2005.

  17. Sax PE, Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Def Syndr 2004, 37:1111–1124.

    Article  CAS  Google Scholar 

  18. Carr A, Miller J, Law M et al.: A syndrome of lipoatrophy, lactic acidaemia, and liver dysfunction associated with HIV nucleoside analogue therapy: contribution of protease inhibitorrelated lipodystrophy syndrome. AIDS 2000, 14:F25-F32.

    Article  PubMed  CAS  Google Scholar 

  19. Brinkman K, Smeitink JA, Romijn JA, et al.: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy. Lancet 1999, 354:1112–1115.

    Article  PubMed  CAS  Google Scholar 

  20. McComsey GA, Paulsen DM, Lonergan JT, et al.: Improvements in lipoatrophy, mitochondrial DNA levels, and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005, 9:15–23.

    Article  Google Scholar 

  21. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 1:48–62.

    Article  Google Scholar 

  22. Murphy R, Zhang J, Hafner R, et al.: Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoatrophy: 24-week results of a prospective randomized clinical trial, AACTG 5110 [abstract]. Proceedings from the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25, 2005.

  23. Milinkovic A, Lopez S, Vidal S, et al.: A randomized open study comparing the effect of reducing stavudine dose versus switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine [abstract]. Proceedings from the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25.

  24. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004, 140:786–794.

    PubMed  CAS  Google Scholar 

  25. Sutinen J, Hakkinen AM, Westerbacka J, et al.: Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study. Antivir Ther 2003, 8:199–207.

    PubMed  CAS  Google Scholar 

  26. Moyle GJ, Lysakova L, Brown S, et al.: A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004, 5:82–87.

    Article  PubMed  CAS  Google Scholar 

  27. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S.Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000, 284:472–477.

    Article  PubMed  CAS  Google Scholar 

  28. Roubenoff R, Weiss L, McDermott A, et al.: A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999, 13:1373–1375.

    Article  PubMed  CAS  Google Scholar 

  29. Kotler DP, Muurahainen N, Grunfeld C, et al.: Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:239–252.

    Article  PubMed  CAS  Google Scholar 

  30. Koutkia P, Canavan B, Breu J, et al.: Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized, controlled trial. JAMA 2004, 292:210–218.

    Article  PubMed  CAS  Google Scholar 

  31. El-Sadr W, Reiss P, De Wit S, et al.: Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes [abstract]. Proceedings from the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25, 2005.

  32. Stein JH, Klein MA, Bellehumeur JL, et al.: Use of HIV-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257–262.

    PubMed  CAS  Google Scholar 

  33. Grunfeld C, Pang M, Doerrler W, et al.: Lipids, lipoproteins, triglyceride clearance, and cytokines in HIV infection and the AIDS. J Clin Endocrinol Metab 1992, 74:1045–1052.

    Article  PubMed  CAS  Google Scholar 

  34. Riddler SA, Smit E, Cole SR, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978–2982.

    Article  PubMed  CAS  Google Scholar 

  35. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000, 14:51–57.

    Article  PubMed  CAS  Google Scholar 

  36. Friis-Møller N, Weber R, Reiss P, et al.: Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy: results from the D:A:D study. AIDS 2003, 17:1179–1193.

    Article  PubMed  Google Scholar 

  37. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for HIV infection. N Engl J Med 2003, 348:702–710.

    Article  PubMed  CAS  Google Scholar 

  38. van Leth F, Phanuphak P, Ruxrungtham K, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253–1263.

    Article  PubMed  Google Scholar 

  39. Wood R, Phanuphak P, Cahn P, et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004, 36:684–692.

    Article  PubMed  CAS  Google Scholar 

  40. Martínez E, Arnaiz JA, Podzamczer D, et al.: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with HIV infection. N Engl J Med 2003, 349:1036–1046.

    Article  PubMed  Google Scholar 

  41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 19:2486–2497.

  42. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  43. Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613–627.

    Article  PubMed  Google Scholar 

  44. Gerber M, Mondy K, Yaraheski K, et al.: Niacin in HIV-infected individuals with hyperlipidemia receiving potent Antiretroviral Therapy. Clin Infect Dis 2004, 39:419–425.

    Article  PubMed  CAS  Google Scholar 

  45. Kris-Etherton PM, Harris WS, Appel LJ, et al.: Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003, 23:151–152.

    Article  PubMed  CAS  Google Scholar 

  46. De Truchis P, Kirstetter M, Perier A, et al.: Treatment of hypertriglyceridemia in HIV-infected patients under HAART by (n-3) polyunsaturated fatty acids: a double blind placebo randomized prospective trial in 122 patients [abstract]. Proceedings from the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25.

  47. Fiore MC, Hatsukami DK, Baker TB: Effective tobacco dependence treatment. JAMA 2002, 288:1768–1771.

    Article  PubMed  Google Scholar 

  48. Stevens LW: JAMA patient page. Kicking the habit. JAMA 2002, 288:532.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AIDS Research and Treatment Unit, University of North Carolina, 211 A West Cameron Avenue, 27599, Chapel Hill, NC, USA

    David Alain Wohl MD

Authors
  1. David Alain Wohl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wohl, D.A. Body shape, lipid, and cardiovascular complications of HIV therapy. Curr HIV/AIDS Rep 2, 74–82 (2005). https://doi.org/10.1007/s11904-005-0022-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-005-0022-6

Keywords

Search

Navigation